- Home
- GENI vs LBRX Comparison
GENI vs LBRX Comparison
Compare GENI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | LBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GENI | LBRX |
|---|---|---|
| Price | $6.61 | $37.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | $10.83 | ★ $57.30 |
| AVG Volume (30 Days) | ★ 7.7M | 337.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.71 | N/A |
| Revenue Next Year | $28.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $14.32 |
| 52 Week High | $12.39 | $50.16 |
Technical Indicators
Market Signals| Indicator | GENI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 40.51 |
| Support Level | $6.55 | $26.75 |
| Resistance Level | $6.74 | $49.74 |
| Average True Range (ATR) | 0.38 | 2.09 |
| MACD | 0.11 | -0.27 |
| Stochastic Oscillator | 82.56 | 37.63 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.